PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia - Zhang, Yingchi; Gao, Yufeng; Zhang, Hui; Zhang, Jingliao; He, Fuhong; Hnízda, Aleš; Qian, Maoxiang; Liu, Xiaoming; Gocho, Yoshihiro; Pui, Ching-Hon; Cheng, Tao; Wang, Qianfei; et al. (Blood, 2018)
Keywords: Angiogenic Proteins - genetics; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Brief Report; Cell Line, Tumor; Child, Preschool; CME; Drug Resistance, Neoplasm - genetics; Humans; Lymphoid Neoplasia; Male; Mutation; Oncogene Proteins, Fusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy; Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics; Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism; Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Receptor, Platelet-Derived Growth Factor beta - genetics; Recurrence; Treatment Outcome; Whole Genome Sequencing